BLCM - Bellicum: Oversold In 2018 And Undervalued 2019
Bellicum Pharmaceuticals (BLCM) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related to the treatment. Although the FDA released the hold in April of 2018, the stock got beat down shortly after the release due to the company executed a 7M share public offering. Subsequently, the stock showed signs of a reversal, but unfortunately, it wasn’t immune to the biotech sector pulldown